key: cord-1006858-3tfqny0q
authors: Cui, Xizhong; Sun, Junfeng; Minkove, Samuel J.; Li, Yan; Cooper, Diane; Couse, Zoe; Eichacker, Peter Q.; Torabi‐Parizi, Parizad
title: Effects of chloroquine or hydroxychloroquine treatment on non‐SARS‐CoV2 viral infections: A systematic review of clinical studies
date: 2021-03-11
journal: Rev Med Virol
DOI: 10.1002/rmv.2228
sha: 92bc26e433f1f47d957860a0084c37650dfd8423
doc_id: 1006858
cord_uid: 3tfqny0q

Chloroquine (CQ) and hydroxychloroquine (HCQ) have been used as antiviral agents for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV2) infection. We performed a systematic review to examine whether prior clinical studies that compared the effects of CQ and HCQ to a control for the treatment of non‐SARS‐CoV2 infection supported the use of these agents in the present SARS‐CoV2 outbreak. PubMed, EMBASE, Scopus and Web of Science (PROSPERO CRD42020183429) were searched from inception through 2 April 2020 without language restrictions. Of 1766 retrieved reports, 18 studies met our inclusion criteria, including 17 prospective controlled studies and one retrospective study. CQ or HCQ were compared to control for the treatment of infectious mononucleosis (EBV, n = 4), warts (human papillomavirus, n = 2), chronic HIV infection (n = 6), acute chikungunya infection (n = 1), acute dengue virus infection (n = 2), chronic HCV (n = 2), and as preventive measures for influenza infection (n = 1). Survival was not evaluated in any study. For HIV, the virus that was most investigated, while two early studies suggested HCQ reduced viral levels, four subsequent ones did not, and in two of these CQ or HCQ increased viral levels and reduced CD4 counts. Overall, three studies concluded CQ or HCQ were effective; four concluded further research was needed to assess the treatments' effectiveness; and 11 concluded that treatment was ineffective or potentially harmful. Prior controlled clinical trials with CQ and HCQ for non‐SARS‐CoV2 viral infections do not support these agents' use for the SARS‐CoV2 outbreak.

Over a short time, the highly transmissible severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) viral infection went from being an outbreak in Wuhan, China to a worldwide pandemic with a mortality rate roughly 10 times greater than seasonal influenza. 1, 2 Faced with this rapidly escalating crisis, clinicians sought therapies that could improve outcomes when combined with standard supportive treatments. Based on in vitro findings that aminoquinoline-4 agents, such as chloroquine (CQ) and hydroxychloroquine (HCQ), inhibited SARS-CoV2 at clinically achievable concentrations [3] [4] [5] and on the widespread use of these agents as anti-malarial and anti-inflammatory agents, both were rapidly introduced into patient care. 6, 7 Early small clinical trials suggested that these agents accelerated SARS-CoV2 clearance and time to clinical recovery. 6, 7 However, observational and larger randomised studies have not consistently substantiated these earlier findings, and several indicate CQ and HCQ may have serious adverse effects in some SARS-CoV2-infected patients. [8] [9] [10] [11] The antiviral activity of aminoquinoline-4 agents is thought to be related to inhibition of virus entry and disruption of viral replication. 12, 13 Based on in vitro and in vivo findings in virus infection models, CQ and HCQ were administered clinically in the past for up to nine different types of noncoronavirus viral infections. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] But at the outbreak of SARS-CoV2, neither agent was being recommended for any of these infections, and a recent narrative review, commentary and editorial suggested that prior clinical studies had not provided strong support for aminoquinoline-4 therapy for viral infection. 32 To comprehensively examine the question of whether prior studies of HCQ and CQ had shown compelling evidence for their benefit in the treatment of other viral infections that would have supported their use for SARS-CoV-2, we performed a systematic review and planned a meta-analysis of clinical studies that were published before the SARS-CoV-2 outbreak. This analysis was designed to compare the effects of an aminoquinoline-4 agent to control for the treatment of any viral infection in earlier studies.

Survival, a main therapeutic goal for these agents in COVID-19 patients, was to be the primary endpoint for the analysis, while viral clearance, biomarkers and organ injury were secondary endpoints.

This systematic review was registered with PROSPERO on May 1 2020 (CRD42020183429) and prepared using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement guidance for literature review and data extraction (File S1).

Using published guidelines 33 and search strategies (File S2), two authors (P.T.P. and P.Q.E.) identified relevant studies in PubMed, EMBASE, Scopus and Web of Science from inception through 2 April 2020 without language restrictions. Published clinical studies in adults that compared the effects of CQ, HCQ or related compounds to a control group on survival (primary endpoint), viral clearance, organ injury or other biologic endpoints during viral infection other than coronavirus (secondary endpoint) were retrieved. Recovered reports were scanned for additional relevant ones.

Four investigators (P.T.P., C.X., Y.L. and P.Q.E.) extracted study data using a standardised extraction form (File S3). If primary and secondary endpoints were not clearly defined in the trial registration, we recorded measures that were most relevant for assessing the efficacy of tested treatments or those emphasised in figures or tables.

Risk of bias was assessed with the Cochrane Collaboration Risk of Bias Assessment Tool for randomised controlled trials and the Newcastle-Ottawa Tool for observational studies. Three investigators (P.T.P., J.S., P.Q.E.) assessed these risks independently and settled disagreements by consensus. Additional parameters of study weakness were also assessed and tabulated separately.

Unless otherwise noted, levels of significance or non-significance (p = ns) reported in the text and/or figures and tables, are those provided by the investigators. In some cases, where analysis was not provided in a report but sufficient data available, we calculated the descriptive statistics and/or treatment differences. Median and interquartile ranges (IQRs) were converted to mean and SD using the method of Wan et al. 34 For HIV, which included the greatest number of studies (n = 6), mean differences between treatment and control groups in changes in blood HIV RNA copy levels (log 10 -transformed) and CD4+ cell counts from pre-to posttreatment were calculated.

Heterogeneity among studies was assessed using the Q statistic and I 2 value. 35 The plan was to analyse the mean differences using random-effect models, 36 if appropriate. However, due to high heterogeneity among studies, we did not combine the studies. Analyses were performed using R 37 (version 4.0.2) with packages meta 38 (version 4.11-0) . In studies also comparing nonaminoquinilone-4 agents to placebo, data are only presented for the comparison between the control and aminoquinilone-4 agent.

We retrieved 18 studies (File S4) comparing the effects of CQ or infection (n = 1). Tables 1-3 and Table S1 summarise the following:   Table 1 , patient populations targeted, study design, the 4-aminoquinilone and control agent studied, and number of control and treatment patients; Table 2, treatment regimens, length of observation and inclusion and exclusion criteria; Table 3, primary and secondary endpoints or measures investigated; Table S1 , enrolment dates, comparisons between groups in baseline parameters and reported adverse events. Seventeen studies were prospective and one retrospective. No study examined the effect of CQ or HCQ on survival, our predefined primary outcome, and only four examined hospitalised patients. The variability of endpoints reported prevented us from proceeding with a meta-analysis of the studies retrieved.

Additionally, because results reported varied dependent on the virus type studied, the studies are presented separately for each virus type.

Three controlled double-blind and one controlled trial compared CQ to placebo in patients with suspected mononucleosis. Only one study provided baseline data. 15 Cowley 15 enrolled 220 hospitalised patients and presented data on 40 hospitalised patients. No descriptive statistics or analysis were reported but based on data shown in the figures, CQ patients had shorter mean (days ± SEM) length of hospital stays (LOS) and duration of subjective symptoms (p ≤ 0.02), but not of fever, pharyngitis or abnormal liver function tests (LFTs; p ≥ 0.07; Figure 1 ). Schumacher 25 placebo. The only measure presented, the mean (±SEM) number of disability days, was not significantly different between groups (no p-value reported; Figure 1 ). No adverse event data were provided.

Two controlled double-blind studies compared the effects of CQ or HCQ to placebo administered for up to 63 days on wart clearance. Partial or no baseline data were presented. Jacobs 18 Figure 1 ). Adverse events were not different between groups in either study.

Five randomised controlled double-blind and one retrospective study examined CQ or HCQ in patients with chronic HIV infection (Tables 1-3 and S1). Sperber compared the effect of HCQ to placebo over 8 weeks in one study 28 and to Zidovudine 27 over 16 weeks in a subsequent one. Limited baseline patient demographic data appeared similar between study groups in each trial. In the first study 28 Compared to pretreatment levels, HCQ decreased plasma HIV RNA counts/min (p = 0.02) and placebo did not (p = ns). Neither HCQ nor placebo significantly altered plasma HIV RNA copies/ml, CD4 counts (Table 4) , serum p24 levels, or tissue culture infecting doses (TCIDs) of virus. We extracted the fold change data for individual patients from their figure and calculated the mean difference (95% confidence interval) between treatment and control. When comparing changes in blood HIV RNA copy levels from pre-to posttreatment, HCQ appeared to decrease viral loads compared to control, as shown in Figure 2 . HCQ decreased IL-6 levels (p = 0.02) but not placebo (p = ns). In the subsequent study, 27 HCQ (n = 35 patients) and

Zidovudine (n = 37) both decreased plasma HIV RNA copies/ml, serum p24 and TCID (p ≤ 0.05 for each) but neither altered CD4 counts. Levels of IL-6 decreased with HCQ (p = 0.03) but not zidovudine (p = ns). There were no adverse events with treatment in either study.

Semrau 26 compared the effects of CQ to sulfadoxine-pyrimethamine (SP; thought to lack anti-HIV activity) treatment on breast milk and plasma HIV RNA in patients with HIV receiving acute anti-malaria treatment. Chart review from the Zambia Exclusive Breast Feeding Study (ZEBS) identified breast feeding women treated for malaria with CQ (n = 18 patients) or SP (n = 12 patients) who had breast milk and plasma samples within 3-16 days of antimalarial treatment. Compared to SP, CQ-treated subjects did not have significantly different breast milk HIV RNA levels (mean ± SD, log 10 copies/ml) (2.59 ± 1.04 vs. 3.14 ± 1.03, respectively, p = 0.21), plasma HIV RNA levels (p = 0.75) or CD4 counts (p = 0.07) ( Table 4 ).

After adjustment for viral loads and CD4 counts at ZEBS enrolment, the authors reported breast milk viral levels were possibly lower with CQ (p = 0.053). Adverse event data were not recorded. In the initial 12 weeks of study, there were a combination of 36 patients in the off-and on-ART control groups and 34 in the CQ groups, see the text.

Author ( Neither treatment reportedly altered plasma HIV RNA levels significantly at 1 or 2 months, and a mean difference we calculated indicated the effects of CQ and placebo did not differ significantly, as shown in Figure 2 . Similarly, CQ did not change CD4 counts (Table 4, Figure 2 ). Adverse event data were not reported. 10 HIV RNA copies/ml) and on blood CD4 cell counts (cells/mm 3 ) in the four studies each these data could be calculated in. Also noted are the drug regimens used in each trial. There was heterogeneity across studies for both measures. Notably, while HCQ appeared to decrease viral levels in Sperber, 28 it increased these in Paton and in patients off antiretroviral therapy (off-ART) in Jacobson (on-ART patients had negative viral levels pretreatment). Neither treatment was associated with an increase in CD4 cell counts and in Paton it decreased them. ART, antiretroviral therapy; CI, confidence interval; CQ, chloroquine; HCQ, hydroxychloroquine CUI ET AL.

-11

off-ART or on-ART patients (p ≥ 0.25), but produced a decrease in the on-ART group for the combined 12 weeks periods following cross-over (p = 0.003). In off-ART patients, CQ increased HIV RNA levels over the first and combined 12 weeks periods (p < 0.001), also shown in our analysis of the effect of CQ on changes from pre-to posttreatment in viral loads compared to control (Figure 2 ). On-ART patients had negative viral loads. CQ did not alter CD4+ counts significantly over the first 12 weeks period in either off-ART or on-ART groups (Table 4, Figure 2 ) but differences for the combined 12

weeks periods could not be determined. CQ was not associated with significant changes in IL-6 levels in either group. No adverse events were reported.

In a randomised double-blind trial, De Lamballerie 16 Seven CQ and no placebo patients described mild adverse events (p < 0.01).

Two randomised double-blind trials compared 3 days of CQ to placebo for patents presenting within 72 h of the onset of suspected dengue fever. In the study by Tricou, 30 Figure 3 ). These measures did not differ significantly comparing the per-protocol populations and secondary endpoints did not differ between groups (p ≥ 0.07). There were more adverse events reported with CQ (p = 0.01).

In the study by Borges, 14 investigators obtained data regarding possible dengue symptoms including fever (axillary temperature ≥ 37.8°C), headache, and retro-orbital, muscle, bone or joint pain in patients with laboratory confirmed infection. Patients were enrolled if they presented with dengue-like symptoms. Of 129 randomised patients, 54 had confirmed dengue infection, of which only 18 placebo and 19 CQ patients completed the study. Baseline data appeared similar between groups. There were reportedly no significant differences in the duration of disease symptoms or the intensity and days of fever comparing groups but no descriptive statistics or analysis are provided. Twelve CQ and no placebo patients described reduced pain intensity and increased ability to do daily chores (p < 0.001). Adverse effects by treatment group were not provided. An a priori sample size of 1500 patients was calculated. A total of 759 patients were randomised to placebo and 757 to CQ. Baseline data were similar between groups. More CQ than placebo patients withdrew (33 vs. 21, p = 0.048). There were no significant differences between groups in laboratory-confirmed clinical influenza (p = 0.376), laboratory only diagnosis (p = 0.261) or clinical diagnosis (p = 0.70; Figure 3 ). One or more adverse events in patients occurred more frequently with CQ (p < 0.0001).

Overall, only three of these eighteen studies concluded that treatment with CQ or HCQ was effective (Table S2 ). Four concluded that study results indicated further research was necessary to assess the tested agent's effectiveness. Eleven studies concluded that CQ or HCQ or the regimens employed had been ineffective. None of the studies included mortality as an endpoint.

Potential risk of bias appeared high among most studies (Table 5) .

Randomisation sequence generation and/or allocation concealment were frequently not reported. Although most studies indicated there was blinding of subjects and personnel at the outset of the study, only one study 22 reported methods to blind outcome assessment from the well-known bitterness and gastrointestinal upset CQ and HCQ produce. 39, 40 This latter weakness is of particular concern since many recorded measures were subjective ones (LOS without discrete discharge criteria and signs and symptoms [pharyngitis, wart clearance, arthralgia, ability to do work]). Eight of the eighteen studies did not report on all randomised patients. Absence of a priori power analyses, incomplete or absent baseline data, and incomplete or absent descriptive statistics weakened many studies as well (Table 6 ). a particular concern in studies presenting subjective findings. Eight studies had high attrition bias due to not providing data on all enrolled patients or high rates of losing patients to follow-up. Only two studies explicitly described the primary and secondary endpoints that we were able to confirm by checking their trial registration. Only a minority of studies provided descriptive statistics along with the results. Finally, no study appeared to be without any of the weaknesses outlined in Table 6 .

Fourth, and most importantly, only 3 of the 18 studies concluded that CQ or HCQ was effective (one study each for mononucleosis, HIV and HCV) and these effects were not reproduced or tested adequately in subsequent studies (Table S2) . Four concluded that further research was necessary to determine the benefits of the agent investigated and the other 11 concluded that treatment was ineffective.

While the studies examined here provided little clinical evidence that CQ or HCQ were effective antiviral agents, whether they demonstrated these agents had minimal risk with viral infection is unclear. Four studies did not report adverse event data or presented insufficient data to compare groups. Six simply reported there were no adverse events in groups. One study in mononucleosis patients reported a cardiac arrest and fatality in one patient that was thought to be related to the infection itself. However, QT interval prolongation is known to occur with these agents and may underlie some of the adverse cardiac events reported in SARs-CoV2 patients. 41 Of the remaining seven studies, three indicated there were no significant differences in adverse events comparing groups (p ≥ 0.08) while four reported significant increases in one or more adverse events in the CQ or HCQ group. Notably, HCQ or CQ were associated with significant increases in viral levels with chronic HIV infection in 14 -

two studies and CQ worsened later stage arthralgia in acute chikungunya infection.

It is noteworthy that, as Table 2 shows, the regimens of CQ and HCQ differed across studies and these differences were sometimes substantial. Some data from the present SARS-CoV-2 outbreak suggest that dosages used in some countries may have only partially achieved maximal tissue concentrations. 42 and that these agents could pose risks for some SARS-CoV2 patients. 32 Another recent systematic review that did not report a PROSPERO registration was consistent with these prior publications. 44 The present systematic review, which included all of the controlled clinical studies presented in these prior reports (except for one paediatric study 45 ) and seven additional ones with EBV, HPV and HIV, further supports these conclusions.

The present study has limitations. First, the differing measures reported and limited number and quality of studies examining treatment for the individual viruses investigated prevented a synthesis and meta-analysis of most available data. Of note, for HIV, the one virus-type a limited quantitative analysis was possible, CQ and HCQ had highly variable effects on CD4 counts, and may have actually increased viral load, although these findings were also variable across studies. Second, it did not include one published randomised open label study of CQ in HIV children, 45 but that study also did not report benefit with treatment. Finally, parameters reported regarding possible severity of disease at baseline differed across studies (e.g., fever and subjective symptoms for EBV; wart number for HPV; CD4 counts and viral load for HIV; fever and joint symptoms for chikungunya; viraemia and antigenemia for acute dengue; LFTs and histology for HCV) and could not be succinctly summarised in a table. However, when comparisons were presented for such baseline parameters between treated and control patients, these were not reportedly different in studies.

The benefits and risks of HCQ and CQ for SARS-CoV2 either administered prophylactically or for acute disease remain controversial. [8] [9] [10] [11] 46 Several recent systematic reviews of this clinical experience have thus far suggested these agents lack clear benefit. 47 

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19. Zhejiang Da Xue Xue Bao Yi Xue Ban

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Observational study of hydroxychloroquine in hospitalized patients with COVID-19

Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State

A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19

Hydroxychloroquine with or without azithromycin in mild-to-moderate COVID-19

Effects of chloroquine on viral infections: an old drug against today's diseases?

A pharmacological perspective of chloroquine in SARS-CoV-2 infection: an old drug for the fight against a new coronavirus?

Chloroquine use improves dengue-related symptoms

Chloroquine in the treatment of infectious mononucleosis

On chikungunya acute infection and chloroquine treatment. Vector Borne Zoonotic Dis

Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients

Effect of chlorquine and placebo on warts

The effect of chloroquine on immune activation and interferon signatures associated with HIV-1

Chloroquine treatment of warts. A double-blind clinical study

Reduction of immune activation with chloroquine therapy during chronic HIV infection

Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial

Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial

New use of an old drug: chloroquine reduces viral and ALT levels in HCV non-responders (a randomized, triple-blind, placebo-controlled pilot trial)

Treatment of infectious mononucleosis

Impact of chloroquine on viral load in breast milk

Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1

Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1

Chloroquine treatment of infectious mononucleosis

A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults

Infectious mononucleosis treated with chloroquine. A double-blind study of 40 cases

Of chloroquine and COVID-19

Preferred Reporting Items For Systematic Reviews and meta-analyses: the PRISMA statement

Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range

Quantifying heterogeneity in a metaanalysis

Meta-analysis in clinical trials

Language and Environment for Statistical Computing

meta: an R package for Meta

Hydroxychloroquine usage in US patients, their experiences of tolerability and adherence, and implications for treatment: survey results from 3127 patients with SLE conducted by the Lupus Foundation of America

Intolerance to hydroxychloroquine marketed in Spain (Dolquine) in patients with autoimmune conditions

Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial

Pharmacokinetic basis of the hydroxychloroquine response in COVID-19: implications for therapy and prevention

Dose-response effects of hydroxychloroquine on prophylaxis against SARS-CoV-2/COVID-19 infection

Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review

Therapeutic potential of chloroquine added to zidovudine plus didanosine for HIV-1 infected children

Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial

A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19

Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19

Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine

Remdesivir for the treatment of COVID-19-final report

Dexamethasone in hospitalized patients with COVID-19

Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial

EBV (mononucleosis) Cowley (1962) High In this report the authors use an encapsulation process to mask the bitterness of HCQ. c This is a cross-over study and the authors do not specify a washout period before crossing from one arm of the study to the other. d In these two reports, randomisation takes place before eligibility is confirmed thus leading to high selection bias. e In this study the authors used capsules. 

The authors declare no conflict of interests.

Parizad